Chicago, IL, United States of America

Arnon Lavie

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 3.1

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2008-2023

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Arnon Lavie: Innovator in Cancer Treatment

Introduction

Arnon Lavie is a prominent inventor based in Chicago, IL (US), known for his significant contributions to cancer treatment through innovative biotechnological advancements. With a total of 7 patents, Lavie has focused on developing L-asparaginase variants that play a crucial role in treating various types of leukemia.

Latest Patents

Among his latest patents, Lavie has developed truncated guinea pig L-asparaginase variants and methods of use. These variants are humanized and described as fusion proteins containing the L-asparaginase, which are utilized in the treatment of cancers such as acute lymphoblastic leukemia and acute myeloid leukemia. Additionally, he has created L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability. These innovations are designed to improve in vivo circulation and are also aimed at treating acute lymphoblastic leukemia and acute myeloid leukemia.

Career Highlights

Throughout his career, Lavie has worked with esteemed institutions such as the University of Illinois and the University of California. His research has significantly impacted the field of oncology, particularly in the development of therapeutic proteins that enhance treatment efficacy for leukemia patients.

Collaborations

Some of his notable coworkers include Manfred Konrad and Farhad Ravandi, who have collaborated with Lavie on various research projects aimed at advancing cancer treatment methodologies.

Conclusion

Arnon Lavie's innovative work in the field of cancer treatment through L-asparaginase variants showcases his dedication to improving patient outcomes. His contributions continue to influence the landscape of biopharmaceuticals and cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…